Ionis Pharmaceuticals Inc (IONS)

Add to Watchlists
Create an Alert
67.96 +0.11  +0.16% NASDAQ Aug 23, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/06/2019 11:30 EST Misc Ionis Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2019
11/06/2019 Earnings Ionis Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
08/07/2019 11:30 EDT Misc Ionis Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/07/2019 Earnings Ionis Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
06/06/2019 14:00 PDT Misc Ionis Pharmaceuticals Inc Annual General Meeting in 2018
05/09/2019 11:30 EDT Misc Ionis Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/09/2019 Earnings Ionis Pharmaceuticals Inc First Quarter Earnings in 2019 Release
03/01/2019 Misc Ionis Pharmaceuticals Inc Annual Report in 2018
02/27/2019 11:30 EST Misc Ionis Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2018
02/27/2019 Earnings Ionis Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.ionispharma.com
  • Investor Relations URL: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Nov. 06, 2019
  • Last Earnings Release: Aug. 07, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.

Top Fund Holders

Symbol Name Weighting
PBE Invesco Dynamic Biotech & Genome ETF 5.30%
FBT First Trust NYSE Arca Biotech ETF 3.41%
WSTBX Ivy Science And Technology B 2.40%
ARKG ARK Genomic Revolution Multi-Sector ETF 2.26%
FBIOX Fidelity® Select Biotechnology 2.22%
LMPFX ClearBridge Aggressive Growth FI 1.90%
XBI SPDR® S&P Biotech ETF 1.60%
IBB iShares Nasdaq Biotechnology ETF 1.32%
FCGSX Fidelity® Series Growth Company 1.26%
FGCKX Fidelity® Growth Company K 1.25%
VISGX Vanguard Small Cap Growth Index Inv 0.48%
VBK Vanguard Small-Cap Growth ETF 0.48%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("IONS","name")
  • Description: =YCI("IONS","description")
  • Sector: =YCI("IONS","sector")
  • Industry: =YCI("IONS","industry")
  • Est. Current Fiscal Year End: =YCI("IONS","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.